These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33210237)

  • 1. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.
    Isla D; de Castro J; García-Campelo R; Majem M; Vicente D; Juan-Vidal O
    Clin Transl Oncol; 2021 Jul; 23(7):1304-1313. PubMed ID: 33210237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
    Isla D; Felip E; Garrido P; Insa A; Majem M; Remon J; Trigo JM; de Castro J
    Clin Transl Oncol; 2023 Jan; 25(1):283-291. PubMed ID: 36168085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
    Isla D; de Castro J; García-Campelo R; Lianes P; Felip E; Garrido P; Paz-Ares L; Trigo JM
    Clin Transl Oncol; 2020 May; 22(5):759-771. PubMed ID: 31368078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
    Hardenberg MC; Patel B; Matthews C; Califano R; Garcia Campelo R; Grohe C; Hong MH; Liu G; Lu S; de Marinis F; Pérol M; Soo RA; Stiles BM; Tiseo M; Tsuboi M
    ESMO Open; 2022 Oct; 7(5):100572. PubMed ID: 36108559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 8. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
    Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E
    Crit Rev Oncol Hematol; 2019 Jun; 138():190-206. PubMed ID: 31092376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
    Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
    Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
    J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.
    Jiang SX; Walton RN; Hueniken K; Baek J; McCartney A; Labbé C; Smith E; Chan SWS; Chen R; Brown C; Patel D; Liang M; Eng L; Sacher A; Bradbury P; Leighl NB; Shepherd FA; Xu W; Liu G; Hurry M; O'Kane GM
    Cancer Med; 2019 Dec; 8(18):7542-7555. PubMed ID: 31650705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
    Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
    J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.
    Yamada Y; Imai H; Sugiyama T; Minemura H; Kanazawa K; Kasai T; Minato K; Kaira K; Kaburagi T
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577852
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
    Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
    Ospina AV; Bolufer Nadal S; Campo-Cañaveral de la Cruz JL; González Larriba JL; Macía Vidueira I; Massutí Sureda B; Nadal E; Trancho FH; Álvarez Kindelán A; Del Barco Morillo E; Bernabé Caro R; Bosch Barrera J; Calvo de Juan V; Casal Rubio J; de Castro J; Cilleruelo Ramos Á; Cobo Dols M; Dómine Gómez M; Figueroa Almánzar S; Garcia Campelo R; Insa Mollá A; Jarabo Sarceda JR; Jiménez Maestre U; López Castro R; Majem M; Martinez-Marti A; Martínez Téllez E; Sánchez Lorente D; Provencio M
    Clin Transl Oncol; 2024 Jul; 26(7):1647-1663. PubMed ID: 38530556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.